Lonsurf® (Trifluridine/Tipiracil) Plus Chemotherapy in Metastatic Colorectal Cancer Prospective Study in Taiwan
Status:
RECRUITING
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Primary Endpoint : To evaluate the Disease control rate (DCR)
Secondary Endpoints:
To evaluate the Progression-free survival (PFS), Overall survival(OS) and Safety profile
Phase:
NA
Details
Lead Sponsor:
Chang Gung Memorial Hospital
Treatments:
Irinotecan trifluridine tipiracil drug combination